BerGenBio ASA logo

BerGenBio ASA

OSL:BGBIO (Norway)  
kr 12.18 (0%) Jul 15
At Loss
P/B:
3.51
Market Cap:
kr 476.08M ($ 44.05M)
Enterprise V:
kr 358.73M ($ 33.20M)
Volume:
78.47K
Avg Vol (2M):
402.32K
Trade In:
Volume:
78.47K
At Loss
Avg Vol (2M):
402.32K

Business Description

Description
BerGenBio ASA is a clinical-stage biopharmaceutical Company focused on developing novel medicines for aggressive diseases. The company's clinical asset, bemcentinib, targeting the receptor tyrosine kinase AXL, is currently in development in a Ph1b/2a study in 1L STK 11 mutated NSCLC and preclinical development for severe respiratory infections.
Name Current Vs Industry Vs History
Cash-To-Debt 280.74
Equity-to-Asset 0.69
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 1.48
Distress
Grey
Safe
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 58.42
9-Day RSI 55.88
14-Day RSI 51.95
6-1 Month Momentum % -59.95
12-1 Month Momentum % 33.03

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.21
Quick Ratio 3.21
Cash Ratio 2.79

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -198.5
Shareholder Yield % -53.12